Starting Lenzetto

If you are starting your patient on Lenzetto®, talking through the different aspects of treatment is essential.

A patient leaflet is available to download below to support your discussions with your patient who has been prescribed Lenzetto® and is about to start their treatment.

What do I need to know when starting
my patient on Lenzetto®?

Taking a break between Lenzetto® and other HRT products is not necessary¹
One spray (90 μL) is the recommended starting dose of Lenzetto®²
It is possible that some symptoms may reappear whilst the patient is becoming established on a new treatment as HRT may take time to impact symptoms²
If after four weeks of continuous treatment with Lenzetto® symptoms persist, this may be because the dose is not high enough.^2,3 The dose of Lenzetto® can be increased to two or three sprays²
When blood tests are being taken as part of menopause management, it might be advised that blood samples are not taken from the arm that Lenzetto® is being applied to, where estradiol levels will be higher

Lenzetto® should be held in the upright position when sprayed²
Lenzetto® should be sprayed in the same position(s) along the arm each day²
Lenzetto® does not need to be rubbed in after being sprayed²
If using sunscreen, this should be applied one hour before Lenzetto®. It should also be avoided on the part of the skin where Lenzetto® will be applied for at least one hour before or after²
The drug application area can be washed after one hour²
Patients should track their Lenzetto® doses each day using the tracker contained on the outside of the Lenzetto® box²

Correct Lenzetto® spray position

Lenzetto® should be held in the
upright position when sprayed.

Using a combination treatment regimen

When oestrogen is prescribed for a postmenopausal woman with a uterus, a progestagen approved for addition to oestrogen treatment should also be initiated for at least 12-14 of every 28-day cycle, to reduce the risk of endometrial cancer. Only progestogens approved for addition to oestrogen treatment should be administered²
When oestrogen is prescribed for a postmenopausal woman who has had a hysterectomy, but has a previous diagnosis of endometriosis, consideration should be given to addition of a progestagen approved for addition to oestrogen to the treatment regimen^2,4

Transdermal HRT is recommended for the following
specific patient populations in local guidelines⁵

Patients with poor symptom control or side effects with oral treatment
Stroke risks e.g. BMI>30, smoker, sedentary
Variable hypertension

History of migraines
Patients on hepatic enzyme inducing agents (e.g. anticonvulsants)
Bowel disorders or absorption problems